Genstar Names Paul N. Clark Operating Partner
8/8/2007
Former ICOS CEO Brings Leadership And Growth Expertise From Over 30 Years Of Pharmaceutical And Life Sciences Industry Experience
Contact: Chris Tofalli
914-834-4334
SAN FRANCISCO, August 8, 2007—Genstar Capital, LLC, a middle market private equity firm that focuses on investments in selected segments of life sciences and healthcare services, industrial technology, business services and software, today announced the appointment of Paul N. Clark as an Operating Partner. Mr. Clark brings over 30 years of experience in the pharmaceutical and life sciences industries, most recently serving as Chairman and CEO of ICOS Corporation. He joins Genstar’s other highly regarded operating partners and advisors who support the firm in its select areas of investment.
Jean-Pierre L. Conte, Chairman and Managing Director of Genstar, said, “We have developed a powerful team of Operating Partners and a network of executive advisors who represent the top talent in their respective fields and they bring immediate value to our firm as we identify and grow investments in our targeted industries. Paul is an extremely talented leader who has extensive experience in running and growing life science companies. He greatly complements our existing team of executives and we look forward to leveraging his expertise as we build strong and profitable businesses in the life sciences sector.”
For the past seven years Mr. Clark served as Chairman, President and CEO of ICOS Corporation where he led the company through considerable growth and value creation with the commercialization of Cialis. He orchestrated the sale of ICOS to Eli Lilly (NYSE: LLY) in January 2007. Prior to joining ICOS, Mr. Clark served in senior executive positions for 14 years with Abbott Laboratories, most recently as Executive Vice President and member of the Board of Directors, running their pharmaceutical division. Before joining Abbot labs he held senior management positions with Marion Laboratories and Sandoz AG.
“Genstar is highly recognized for its life sciences investments and I expect to add value to current and future portfolio companies. Genstar has a history of working well with people who have operating experience in helping to truly improve and build companies,” said Mr. Clark.
Mr. Clark, 60, holds a B.S. degree from the University of Alabama and an MBA from the Tuck School of Business at Dartmouth College. He currently serves on the boards of Agilent Technologies, Inc., Swedish Hospital, and the Western Golf Association/Evans Scholars Foundation.
Genstar’s healthcare investments currently include 21st Services, a leading supplier of life expectancy estimates to brokers, providers and investors, as they determine the valuation for a policy; OnCURE Medical Corporation, which owns, operates and manages treatment centers exclusively focused on providing the most state-of-the-art radiation treatment alternatives; Harlan Sprague Dawley, Inc., a leading provider of preclinical products and services for the pharmaceutical and biotechnology industries; Catalent Pharma Solutions, formerly Pharmaceutical Technologies and Services, a division of Cardinal Health, the leading contract manufacturing and service provider for the pharmaceutical industry; and PRA International (NASDAQ: PRAI), a leading international clinical research organization.
About Genstar Capital, LLC
Based in San Francisco, Genstar Capital (www.gencap.com) is a private equity investment firm that makes leveraged investments in quality middle-market companies. Genstar Capital works in partnership with management to transform its portfolio companies into industry-leading businesses. With more than $3 billion of committed capital under management and significant experience investing in businesses, Genstar focuses on selected segments of life science and healthcare services, industrial technology, business services and software services.